Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: The National Opioid Medications Abuse Deterrence (NOMAD) study protocol

Addiction

Volumn 110, Issue 2, 2015, Pages 226-237

  Degenhardt, Louisa ^a,b,c,d   Larance, Briony ^a   Bruno, Raimondo ^e   Lintzeris, Nicholas ^f,g   Ali, Robert ^h   Farrell, Michael ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF TASMANIA   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g SOUTH EASTERN SYDNEY LOCAL HEALTH DISTRICT   (Australia)

^h UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Abuse deterrence; Diversion; Opioid dependence; Pharmaceutical opioids; Post marketing surveillance; Tamper resistant formulations

Indexed keywords

NARCOTIC ANALGESIC AGENT; OXYCODONE; STREET DRUG;

ADOLESCENT; ADULT; AGED; AUSTRALIA; CHEMISTRY; HUMAN; MEDICATION COMPLIANCE; MEDICINAL CHEMISTRY; MIDDLE AGED; OPIOID-RELATED DISORDERS; POSTMARKETING SURVEILLANCE; PRESCRIPTION DRUG DIVERSION; PRESCRIPTION DRUG MISUSE; PREVENTION AND CONTROL; PROCEDURES; PROSPECTIVE STUDY; SUPPLY AND DISTRIBUTION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANALGESICS, OPIOID; AUSTRALIA; CHEMISTRY, PHARMACEUTICAL; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; OPIOID-RELATED DISORDERS; OXYCODONE; PRESCRIPTION DRUG DIVERSION; PRESCRIPTION DRUG MISUSE; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; STREET DRUGS; YOUNG ADULT;

EID: 84922980838     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12746     Document Type: Article

References (52)

1. Leong M., Murnion B., Haber P. S. Examination of opioid prescribing in Australia from 1992 to 2007. Intern Med J 2009; 39: 676-681. doi: 10.1111/j.1445-5994.2009.01982.x.
2. Compton W. M., Volkow N. D. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend 2006; 81: 103-107.
3. Degenhardt L., Black E., Breen C., Bruno R. Trends in morphine prescriptions, illicit morphine use and associated harms among regular injecting drug users in Australia. Drug Alcohol Rev 2006; 25: 403-412.
4. Noble M., Treadwell J. R., Tregear S. J., Coates V. H., Wiffen P. J., Akafomo C. etal. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010; (1): CD006605.
5. Larance B., Degenhardt L., Lintzeris N., Winstock A., Mattick R. Definitions related to the use of pharmaceutical opioids: extramedical use, diversion, non-adherence and aberrant medication-related behaviours. Drug Alcohol Rev 2011; 30: 236-245.
6. Paulozzi L. J., Budnitz D. S., Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf 2006; 15: 618-627.
7. Compton W. M., Volkow N. D. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 2006; 83: S4-S7.
8. Saunders J. Substance dependence and nondependence in DSM and the ICD. In: Saunders J., Schuckit M. A., Sirovatka P. J., Regier D. A., editors. Diagnostic Issues in Substance Use Disorders: Refining the Research Agenda for DSM-V. Arlington, VA: American Psychiatric Association; 2007, pp. 75-92.
9. World Health Organization. Lexicon of alcohol and drug terms. 2009. Available at: http://www.who.int/substance:abuse/terminology/who_lexicon/en/print.html (accessed 29 September 2009).
10. Trescot A. M., Datta S., Lee M., Hansen H. Opioid pharmacology. Pain Physician 2008; 11: S133-153.
11. Quinn D. I., Wodak A., Day R. O. Pharmacokinetic and pharmacodynamic principles of illit drug use and treatment of illicit drug users. Clin Pharmacokinet 1997; 33: 344-400.
12. Schuster C. R. History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs. Drug Alcohol Depend 2006; 83: S8-14.
13. Grudzinskas C., Balster R. L., Gorodetzky C. W., Griffiths R. R., Henningfield J. E., Johanson C.-E. etal. Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report. Drug Alcohol Depend 2006; 83: S77-82.
14. Romach M., Schoedel K., Sellers E. Update on tamper-resistant drug formulations. Drug Alcohol Depend 2013; 130: 13-23.
15. Katz N., Dart R. C., Bailey E. J., Trudeau J., Osgood E., Paillard F. Tampering with prescription opioids: nature and extent of the problem, health conequences, and solutions. Am J Drug Alcohol Abuse 2011; 37: 205-217.
16. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Abuse-Deterrent Opioids-Evaluation and Labeling. Rockville, MD: Food and Drug Administration; 2013, Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf (accessed 31 August 2014).
17. Loimer N., Presslich O., Grunberger J., Linzmayer L. Combined naloxone/methadone preparations for opiate substitution therapy. J Subst Abuse Treat 1991; 8: 157-160.
18. Cone E. J. Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet. Drug Alcohol Depend 2006; 83S: S31-39.
19. Fudala P. J., Johnson R. E. Development of opioid formulations with limited diversion and abuse potential. Drug Alcohol Depend 2006; 83: S40-47.
20. Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep 2008; 10: 11-18.
21. Anonymous. Controlled prescription drug abuse at epidemic level. J Pain Palliat Care Pharmacother 2006; 20: 61-64.
22. Cicero T. J., Inciardi J. A., Muñoz A. Trends in abuse of OxyContin and other opioid analgesics in the United States: 2002-2004. J Pain 2005; 6: 662-672.
23. Cicero T. J., Inciardi J. A., Surratt H. Trends in the use and abuse of branded and generic extended release oxycodone and fentanyl products in the United States. Drug Alcohol Depend 2007; 91: 115-120.
24. Daniulaityte R., Carlson R. G., Kenne D. R. Initiation to pharmaceutical opioids and patterns of misuse: preliminary qualitative findings obtained by the Ohio Substance Abuse Monitoring Network. J Drug Issues 2006; 36: 787-808.
25. Dhalla I. A., Mamdani M. M., Sivilotti M. L. A., Kopp A., Qureshi O., Juurlink D. N. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. Can Med Assoc J 2009; 181: 891-896.
26. General Accounting Office. Prescription Drugs: OxyContin Abuse and Diversion and Efforts to Address the Problem (GAO-04-110). Washington, DC: GPO. Available at: 2003. http://www.gao.gov/new.items/d04110.pdf (accessed 30 May 2014).
27. Butler S. F., Cassidy T. A., Chilcoat H., Black R. A., Landau C., Budman S. H. etal. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain 2012; 14: 351-358.
28. Butler S. F., Cassidy T. A., Chilcoat H., Black R. A., Landau C., Budman S. H. etal. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain 2013; 14: 351-358.
29. Severtson S. G., Bartelson B. B., Davis J. M., Muñoz A., Schneider M. F., Chilcoat H. etal. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain 2013; 14: 1222-1230.
30. Havens J. R., Leukefeld C. G., DeVeaugh-Geiss A. M., Coplan P., Chilcoat H. D. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers. Drug Alcohol Depend 2014; 139: 9-17.
31. National Drug and Alcohol Research Centre. A Review of Opioid Prescribing in Tasmania: A Blueprint for the Future. Sydney: NDARC, University of New South Wales; 2012.
32. Roxburgh A., Bruno R., Larance B., Burns L. Prescription of opioid analgesics and related harms in Australia. Med J Aust 2011; 195: 280-284.
33. IMS Health. N2A Sales Data. 2013.
34. MIMs Australia. Mims Online. Australia: MIMs. Available at: 2013. https://www.mimsonline.com.au/Search/Search.aspx (accessed October 2014).
35. The PLOS Medicine Editors. Observational studies: getting clear about transparency. PLOS Med 2014; 11: e1001711. doi: 10.1371/journal.pmed.1001711.
36. Cao W., Treloar C. Comparison of needle and syringe programme attendees and non-attendees from a high drug-using area in Sydney, New South Wales. Drug Alcohol Rev 2006; 25: 439-444.
37. Gilmour S., Degenhardt L., Hall W., Day C. Using intervention time series analyses to assess the effects of imperfectly identifiable natural events: a general method and example. BMC Med Res Methodol 2006; 6: 16.
38. Gilmour S., Koch I., Degenhardt L., Day C. Identification and quantification of change in Australian illicit drug markets. BMC Public Health 2006; 6: 200.
39. Degenhardt L., Conroy E., Day C., Gilmour S., Hall W. The impact of a reduction in drug supply on demand for and compliance with treatment for drug dependence. Drug Alcohol Depend 2005; 79: 129-135. doi: 10.1016/j.drugalcdep.2005.01.018.
40. Degenhardt L., Conroy E., Gilmour S., Hall W. The effect of a reduction in heroin supply upon population trends in fatal and non-fatal drug overdoses. Med J Aust 2005; 182: 20-23.
41. Degenhardt L., Day C., editors. The Course and Consequences of the Heroin Shortage in NSW. NDLERF Monograph no. 4. Adelaide: Australasian Centre for Policing Research. Available at: 2004. http://www.ndlerf.gov.au/publications/monographs/monograph-4 (accessed 30 May 2014).
42. Stafford J., Burns L. Australia Drug Trends 2012: Findings from the Illicit Drug Reporting System (IDRS). Australian Drug Trends Series no. 91. Sydney: National Drug and Alcohol Research Centre, University of New South Wales; 2013.
43. Haro J. M., Arbabzadeh-Bouchez S., Brugha T. S., De Girolamo G., Guyer M. E., Jin R. etal. Concordance of the Composite International Diagnostic Interview Version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO World Mental Health surveys. Int J Methods Psychiatr Res 2006; 15: 167-180.
44. Bush K., Kivlahan D. R., McDonell M. B., Fihn S. D., Bradley K. A. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med 1998; 158: 1789-1795.
45. Gossop M., Darke S., Griffiths P., Hando J., Powis B., Hall W. etal. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 1995; 90: 607-614.
46. Butler S., Benoit C., Budman S., Fernandez K., McCormick C., Venuti S. etal. Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct J 2006; 3: 5.
47. Tan G., Jensen M. P., Thornby J. I., Shanti B. F. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain 2004; 5: 133-137.
48. Skevington S. M., Lotfy M., O'Connell K. A. The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res 2004; 13: 299-310.
49. Kroenke K., Spitzer R. L., Williams J. B. The PHQ-9. J Gen Intern Med 2001; 16: 606-613.
50. Spitzer R. L., Kroenke K., Williams J. B., Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166: 1092.
51. Cummins R., Eckersley R., Pallant J., van Vugt J., Misajon R. Developing a national index of subjective wellbeing: the Australian unity wellbeing index. Soc Indic Res 2003; 64: 159-190. doi: 10.1023/a:1024704320683.
52. Degenhardt L., Bruno R., Gilmour S., Campbell G., Mattick R. P., Shand F. etal. Estimating the proportion of prescription opioid consumption in Australia that is accounted for by people who inject drugs. Drug Alcohol Rev 2013; 32: 468-474.